Advertisement

Topics

Latest Drug Discovery NewsRSS

04:11 EST 23rd January 2019 | BioPortfolio

$BHVN Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy https://www.prnewswire.com/news-releases/biohaven-receives-fda-may-proceed-letter-for-phase-3-clinical-trial-of-bhv-3241-for-multiple-system-atrophy-3

$BHVN Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy https://www.prnewswire.com/news-releases/biohaven-receives-fda-may-proceed-letter-for-phase-3-clinical-trial-of-bhv-3241-for-multiple-system-atrophy-300782415.html …

Dolomite Bio Maintains Rapid Growth Trajectory and Launches Novel Products throughout 2018

Dolomite Bio, part of the Blacktrace group, is helping to drive forward the single cell genomics revolution. Single cell analysis promises to transform drug discovery and disease research, enabling scientists to investigate cell diversity and quantify gene expression at the cellular level. This up and coming market sector is forecast to be worth $5.9bn by 2025*, with revenue growth driven by an in...

PeptiDream Announces New Peptide Drug Conjugate (PDC) Discovery Deal with Shionogi

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a multi-program collaborative research agreement with Osaka-based Shionogi & Co., Ltd (“Shionogi”)(TOKYO:4507) for the discovery and development of a series of blood brain barrier (BBB) penetrating peptide drug-...

SpeeDx Increase European Distribution Network

Comprehensive coverage achieved with signing of AB ANALITICA and Immuno Diagnostic Oy SpeeDx have announced signing two new distribution partners, creating comprehensive access for customers to market-leading SpeeDx ResistancePlus® and PlexPCR® tests across Europe. AB ANALITICA will distribute throughout Italy and Immuno Diagnostic Oy will cov...

Verified Clinical Trials and ClinSpark® Now To Offer Single Access Point For eSource and Research Subject Verification To Prevent Duplicate Subjects in Clinical Trials

The global research subject duplicate enrollment prevention solution Verified Clinical Trials (VCT) and Foundry Health’s eSource and phase I automation platform ClinSpark are now electronically connected. The integration greatly simplifies the process for site users to check for duplicate subject enrollments and several other protocol violations. GARDEN CITY, N.Y. (PRWEB) January 23, 2019 The g...

ACRP Elects John Neal, Founder and Chairman of PCRS Network™, as 2019 Chairman

Largest Association of Clinical Researchers Elects John Neal as 2019 Chairman. With a Focus on Education and Sponsor Involvement, Neal Aims to Accelerate Clinical Research. ARLINGTON, Va. (PRWEB) January 22, 2019 Everyday, thousands of people die waiting for new drugs or therapies to reach the market because of drug and therapy study delays. It also costs pharmaceutical companies almost $3 millio...

Rep. Elijah Cummings put the #pharmaceutical #industry on notice this week when he launched an investigation into the industry’s drug pricing tactics. https://buff.ly/2UcDO6p 

Rep. Elijah Cummings put the #pharmaceutical #industry on notice this week when he launched an investigation into the industry’s drug pricing tactics. https://buff.ly/2UcDO6p 

AHF Criticizes White House Appointment of Joe Grogan, Former Gilead Lobbyist, as Domestic Policy Advisor

AIDS group laments fact that Washington’s revolving door continues: private industry executives cycle into key government positions, then back to private sector—often to the detriment of the public good The White House announced that U.S. President Donald Trump has appointed Joe Grogan to serve as Domestic Policy Adviser on his White House staff (Po

FSD Pharma Strengthens Drug Development With GW Executive

Rupert Haynes and Raza Bokhari, with FSD Pharma discuss the company’s pharma initiative, synthetic cannabinoids and extraction methods. The post FSD Pharma Strengthens Drug Development With GW Executive appeared first on Investing News Network.

ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines

SINGAPORE, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that new pre-clinical data on varlitinib’s activity in triple negative breast cancer (TNBC) cell lines have been published online ...

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of Part A of the PROLONG trial in preterm labor. In this trial, O...

Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of Part A of the PROLONG trial in preterm labor. In this trial...

Tenax Therapeutics Working on Phase 2 Trial

Anthony DiTonno, CEO of Tenax Therapeutics, talks about what’s on the horizon for the development of its drug, levosimendan and financing. The post Tenax Therapeutics Working on Phase 2 Trial appeared first on Investing News Network.

Content that Clicks: Syneos Health Publishes Report on Social Media Marketing for Clinical Trial Recruitment

75% of Americans seek medical information online at least once a month—and yet, just 11% of clinical trials implement social-media efforts to recruit participants. Perhaps consequently, nearly half of all clinical trials fail to meet their target enrollment numbers. There is staggering potential for growth. To that end, Syneos Health conducted a study to determine, […] The post Content tha...

I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5

SHANGHAI, Jan. 22, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, announced on January 18th, 2019 that the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study for TJD5 in patients...

STAT Plus: STAT's national #biotech reporter Damian Garde delved into new approaches, examined case studies, and fielded questions about the future of clinical trials. https://buff.ly/2U8nJyn 

STAT Plus: STAT's national #biotech reporter Damian Garde delved into new approaches, examined case studies, and fielded questions about the future of clinical trials. https://buff.ly/2U8nJyn 

STAT Plus: Webinar: The future of clinical trials

STAT's national biotech reporter Damian Garde delved into new approaches, examined case studies, and fielded questions about the future of clinical trials.

KOL Perspectives: Rituximab Use in Lupus [Report Updated: 02072018] Prices from USD $2500

KOL Perspectives: Rituximab Use in LupusSummaryThis KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.Questions topics Current future use of RTX in lupus Views on RTX's Phase II/III EXPLORER trial reanalysis Opinion on data demonstrating that RTX is effective for the management of refractory SLE Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination th...

U.S. FDA Accepts sNDAs for PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)

Dateline City: KENILWORTH, NJ Potential New Indication Would Expand Use to Allow Treatment-Experienced Adults Living with HIV-1 Whose Virus is Suppressed to Switch to PIFELTRO (in Combination with Other Antiretrovirals) or DELSTRIGO KENILWORTH, N.J., Jan. 22, 2019 – Merck (NY...

Price Disclosure Legislation Unlikely to Lower Drug Costs

NewsThe Trump administration's proposal to require pharmaceutical companies to publish drug prices in TV ads is unlikely to help control drug prices.Con

Researchers Work to Repurpose Drug to Battle Rare MPS Diseases

NewsMount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS).

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day...

STAT Plus: U.S. Supreme Court upholds disputed language in patent law, giving generic drug makers a big win. https://buff.ly/2Wa0SEx 

STAT Plus: U.S. Supreme Court upholds disputed language in patent law, giving generic drug makers a big win. https://buff.ly/2Wa0SEx 

United Imaging Healthcare uEXPLORER Total-body Scanner Cleared by FDA, Available in U.S. Early 2019

World's first medical imaging 3D scanner capable of capturing whole human body at one bed position HOUSTON, Jan. 22, 2019 /PRNewswire/ -- United Imaging Healthcare (United Imaging), an international leader in advanced medical imaging and radiotherapy equipment, today announced US Food & Drug Administration (FDA) clearance of the uEXPLORER total-...

Mom Bomb, Look Beauty win DSN/ECRM Buyers’ Choice Awards

Mom Bomb won the Drug Store News/ECRM

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Drug Discovery market research data and corporate reports here